Researchers have identified a positive correlation between hemolytic disease of the fetus and newborn (HDFN) survival and the World Bank income class of the country where the pregnancy took place.
HDFN pregnancies with multiple types of antibodies against the fetal red blood cells require cooperation between specialties for treatment.
A potential HDFN treatment has shown promising clinical results and will now move to a phase 3 trial.
For newborns diagnosed with hemolytic disease of the fetus and newborn (HDFN), a delayed clamping of the umbilical cord during delivery appears to be beneficial and safe, according to a recently published study.
A recent study found that a monocyte monolayer assay (MMA) appears to accurately predict the severity of hemolytic disease of the fetus and newborn (HDFN).
A study found that HDFN patients who underwent an intrauterine transfusion have an increased risk of needing another in their next pregnancies.
A noninvasive screening program in Switzerland has shown promising results, allowing preventative measures against hemolytic disease of the fetus and newborn (HDFN) only in pregnancies that require it.
A recently published report shows a combination of intensive treatment with ultraviolet light (phototherapy) and injected human antibodies (immunoglobulin) was successful in an infant with HDFN.
The antibodies responsible for hemolytic disease of the fetus and newborn (HDFN) could be transmitted to newborns through breast milk, case studies show.
A small study shows a new noninvasive test could enable the diagnosis of hemolytic disease of the fetus and newborn (HDFN) in the third trimester.
